mirtazapine and desipramine

mirtazapine has been researched along with desipramine in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (45.45)29.6817
2010's11 (50.00)24.3611
2020's1 (4.55)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J1
Buck, LB; Petrascheck, M; Ye, X1
Lombardo, F; Obach, RS; Waters, NJ1
Kenny, PW; Toulmin, A; Wood, JM1
Ahman, M; Holmén, AG; Wan, H1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Alix, K; Dukat, M; Khatri, S; Schulte, MK; Worsham, J1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bouvard, M; Rénéric, JP; Stinus, L1
Devoto, P; Flore, G; Gessa, GL; Longu, G; Pira, L1
Fisar, Z; Hroudová, J; Raboch, J1
Fuzikawa, C; Hara, C; Lopes Rocha, F; Ramos, MG; Riera, R1
Arteta, B; Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Grygier, B; Kubera, M; Lasoń, W; Leśkiewicz, M; Maes, M1
Baj, G; Bernareggi, A; Bittolo, T; Deiana, C; Ferrazzo, S; Raminelli, CA; Tongiorgi, E; Vaghi, V1
García-Fuster, MJ; García-Sevilla, JA1
Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X1
Arteta, B; Curzytek, K; Grygier, B; Kubera, M; Maes, M; Malicki, S1

Reviews

3 review(s) available for mirtazapine and desipramine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Antidepressant combination for major depression in incomplete responders--a systematic review.
    Journal of affective disorders, 2013, Jan-10, Volume: 144, Issue:1-2

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Randomized Controlled Trials as Topic; Treatment Outcome

2013
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride

2016

Other Studies

19 other study(ies) available for mirtazapine and desipramine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
    Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2

    Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase

2008
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
    Nature, 2007, Nov-22, Volume: 450, Issue:7169

    Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevity; Methiothepin; Mianserin; Octopamine; Receptors, Biogenic Amine; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; Starvation

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Toward prediction of alkane/water partition coefficients.
    Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13

    Topics: Alkanes; Central Nervous System; Molecular Structure; Static Electricity; Surface Properties; Water

2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
    Bioorganic & medicinal chemistry letters, 2013, Nov-01, Volume: 23, Issue:21

    Topics: Amination; Animals; Antidepressive Agents; Anura; Halogenation; Hindlimb Suspension; Mice; Quinazolines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
    Behavioural brain research, 2002, Nov-15, Volume: 136, Issue:2

    Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Clonidine; Cyclopropanes; Depression; Desipramine; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Motor Activity; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Swimming

2002
Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex.
    European journal of pharmacology, 2004, Mar-08, Volume: 487, Issue:1-3

    Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Clonidine; Desipramine; Dopamine; Injections, Intraperitoneal; Male; Mianserin; Microdialysis; Mirtazapine; Neurons; Norepinephrine; Occipital Lobe; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System

2004
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
    Neuro endocrinology letters, 2010, Volume: 31, Issue:5

    Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride

2010
Inhibitory effect of antidepressants on B16F10 melanoma tumor growth.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:3

    Topics: Animals; Antidepressive Agents; Cell Proliferation; Desipramine; Fluoxetine; Interleukin-10; Male; Melanoma, Experimental; Mianserin; Mice; Mice, Inbred C57BL; Mirtazapine; T-Lymphocytes; Tumor Cells, Cultured

2013
Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.
    Scientific reports, 2016, Jan-25, Volume: 6

    Topics: Animals; Antidepressive Agents; Atrophy; Breath Tests; Cerebral Cortex; Desipramine; GABAergic Neurons; gamma-Aminobutyric Acid; Heart Rate; Humans; Methyl-CpG-Binding Protein 2; Mianserin; Mice; Mirtazapine; Rett Syndrome; Seizures; Somatosensory Cortex

2016
Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.
    Psychopharmacology, 2016, Volume: 233, Issue:15-16

    Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Apoptosis; Autoreceptors; Blotting, Western; Brain; CASP8 and FADD-Like Apoptosis Regulating Protein; Cerebral Cortex; Clorgyline; Desipramine; Electroshock; Excitatory Amino Acid Antagonists; Fas-Associated Death Domain Protein; Fluoxetine; Idazoxan; Indans; Ketamine; Male; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Phosphoproteins; Phosphorylation; Rats; RNA-Binding Proteins; Thiazoles

2016
Stimulatory effect of fluoxetine and desipramine, but not mirtazapine on C26 colon carcinoma hepatic metastases formation: association with cytokines.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Animals; Antidepressive Agents; Carcinoma; Colonic Neoplasms; Cytokines; Desipramine; Fluoxetine; Liver Neoplasms; Male; Mice; Mirtazapine

2023